Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
IPO Year: 2014
Exchange: NYSE
Website: nevro.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | $4.50 → $5.85 | Underperform → Hold | Jefferies |
| 2/7/2025 | $6.00 → $5.85 | Neutral → Overweight | Piper Sandler |
| 12/3/2024 | $5.00 | Equal Weight | Wells Fargo |
| 12/2/2024 | $9.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 8/9/2024 | Sell → Neutral | Citigroup | |
| 8/8/2024 | Underperform → Peer Perform | Wolfe Research | |
| 8/7/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/7/2024 | Neutral → Underweight | JP Morgan | |
| 8/7/2024 | $13.00 → $5.50 | Equal Weight → Underweight | Wells Fargo |
| 5/22/2024 | $13.50 → $9.00 | Neutral → Sell | Citigroup |
REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.
REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induceme
Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024 REDWOOD CITY, Calif., Jan. 13, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth-quarter and full-year 2024 revenue and other financial results. Preliminary, Unaudited Financial Highlights Fourth-quarter 2024 worldwide revenue is expected to be approximately $105 million to $106 million, representing a decrease of 9% to 10% on a reported and constant currency basis compared with the fourth quarter of 2023;
REDWOOD CITY, Calif., Dec. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on December 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,000 shares of Nevro's common stock to 20 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material inducem
Furthering Nevro's body of evidence as an innovation leader in pain management, data highlights the company's posterior integrated transfixation cage system REDWOOD CITY, Calif., Nov. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1™ SI Joint Fusion System ("Nevro1"), a posterior integrated transfixation cage system offering enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindric
REDWOOD CITY, Calif., Nov. 15, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on November 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 37,726 shares of Nevro's common stock to 24 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material inducem
HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* REDWOOD CITY, Calif., Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received CE Mark Certification in Europe for its HFX iQ™ spinal cord stimulation (SCS) system. The CE marking allows Nevro to market HFX iQ in all countries that recognize this certification.
Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma
Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif., Oct. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy (P
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously
Piper Sandler upgraded Nevro from Neutral to Overweight and set a new price target of $5.85 from $6.00 previously
Wells Fargo initiated coverage of Nevro with a rating of Equal Weight and set a new price target of $5.00
Morgan Stanley downgraded Nevro from Equal-Weight to Underweight and set a new price target of $4.00 from $9.00 previously
Citigroup upgraded Nevro from Sell to Neutral
Wolfe Research upgraded Nevro from Underperform to Peer Perform
JMP Securities downgraded Nevro from Mkt Outperform to Mkt Perform
JP Morgan downgraded Nevro from Neutral to Underweight
Wells Fargo downgraded Nevro from Equal Weight to Underweight and set a new price target of $5.50 from $13.00 previously
Citigroup downgraded Nevro from Neutral to Sell and set a new price target of $9.00 from $13.50 previously
15-12G - NEVRO CORP (0001444380) (Filer)
EFFECT - NEVRO CORP (0001444380) (Filer)
SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)
SC 13G - NEVRO CORP (0001444380) (Subject)
SC 13D/A - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13G/A - NEVRO CORP (0001444380) (Subject)
SC 13D/A - NEVRO CORP (0001444380) (Subject)
SC 13G - NEVRO CORP (0001444380) (Subject)
SC 13G - NEVRO CORP (0001444380) (Subject)
Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi
REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately. "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and
REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately. "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a
REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.
Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma
REDWOOD CITY, Calif., Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. The company will also host a conference call beginning at 1:30 p.m. PST (4:30 p.m. EST) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For th
Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, Calif., Aug. 6, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its second-quarter 2024 financial results, revised its full-year 2024 guidance, and issued third-quarter 2024 guidance. The company also announced that it is initiating a process
REDWOOD CITY, Calif., July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the second quarter of 2024 after the market closes on Tuesday, August 6, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For thos
Announces Additional Restructuring Steps to Advance Strategy and Accelerate Profitability Raises Adjusted EBITDA Guidance and Reaffirms Revenue Guidance for Full-Year 2024 Promotes Christofer Christoforou to Chief Operating Officer REDWOOD CITY, Calif., May 7, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results. The company also announced additional restructuring steps to advance its strategy and accelerate profitability, raised its adjusted EBITDA guidance and reaffirmed its revenue guidance for the full-year 2024, and
REDWOOD CITY, Calif., April 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For those
Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ --Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2023 financial results. The company also provided first-quarter and full-year 2024 financial guidance. "Our fourth quarter performance reflects continued execution of our three-pillar strategy initiated in the second quarter of 2023," said Kevin Thornal, Nevro's CEO and president. "The actions we have taken, including our commercial realignment, strengthening our executive team with talented and e
REDWOOD CITY, Calif., Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Wednesday, February 21, 2024. The company will also host a conference call on February 21, 2024 to discuss its financial results. The call will begin at 1:30 pm PT / 4:30 pm ET. Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S. or +1 (240) 789-2728 internationally, using conference ID: 3583097. A